Prognostic indices in diffuse large B-cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R-CHOP 14 versus 21 phase 3 trial

Mary Gleeson, Nicholas Counsell, David Cunningham, Anthony Lawrie, Laura Clifton-Hadley, Eliza Hawkes, Andrew McMillan, Kirit M. Ardeshna, Cathy Burton, Nick Chadwick, Joanna Gambell, Paul Smith, Paul Mouncey, Christopher Pocock, John Radford, John Davies, Deborah Turner, Anton Kruger, Peter Johnson, David Linch

Research output: Contribution to journalArticlepeer-review

Abstract

We compared the International Prognostic Index (IPI), Revised (R)-IPI and age-adjusted (aa)-IPI as prognostic indices for patients with diffuse large B-cell lymphoma (DLBCL) in the UK National Cancer Research Institute (NCRI) R-CHOP 14 versus 21 trial (N = 1080). The R-IPI and aa-IPI showed no marked improvement compared to the IPI for overall and progression-free survival, in terms of model fit or discrimination. Similar results were observed in exploratory analyses incorporating the Grupo Español de Linfomas/Transplante de Médula Ósea (GELTAMO)-IPI, where baseline β2-microglobulin data were available (N = 655). Although our findings support current use of the IPI, a novel prognostic tool to better delineate a high-risk DLBCL group in the rituximab era is needed.

Original languageEnglish
Pages (from-to)1015-1019
Number of pages5
JournalBritish Journal of Haematology
Volume192
Issue number6
Early online date29 May 2020
DOIs
Publication statusPublished - 16 Mar 2021

Keywords

  • clinical trials
  • diffuse large B-cell lymphoma
  • international prognostic index
  • rituximab

Research Beacons, Institutes and Platforms

  • Manchester Cancer Research Centre

Fingerprint

Dive into the research topics of 'Prognostic indices in diffuse large B-cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R-CHOP 14 versus 21 phase 3 trial'. Together they form a unique fingerprint.

Cite this